Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16396
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCorfield, Julia-
dc.contributor.authorCrozier, Jack-
dc.contributor.authorJoshua, Anthony-
dc.contributor.authorBolton, Damien M-
dc.contributor.authorLawrentschuk, Nathan-
dc.date2016-10-06-
dc.date.accessioned2016-11-03T04:23:34Z-
dc.date.available2016-11-03T04:23:34Z-
dc.date.issued2016-10-
dc.identifier.citationBJU International 2016; 118(S3): 8-13en_US
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/16396-
dc.description.abstractOBJECTIVES: To examine the current literature and identify key consensus findings from the available studies to better educate urologists and medical oncologists on agents used in the treatment of metastatic prostate cancer (mPC). METHODS: Following PRISMA guidelines, we conducted a systematic review of the available literature on reported trials of systemic therapies for mPC. Two search terms were used: 'metastatic prostate cancer' and 'treatment'. RESULTS: A variety of agents have demonstrated improved overall survival in patients with mPC. Twenty recently documented trials were reported in the literature with a focus on enzalutamide, abiraterone acetate, docetaxel and other newer agents. These studies were grouped based on patient populations. CONCLUSION: The increasing number of high-quality clinical trials, with overlapping patient populations has made defining the correct therapy for men with mPC challenging for urologists and medical oncologists. The data suggests that the optimal sequence of drugs is not only unknown but also not necessarily the same for each patient. As such, we suggest a more individualized approach to the treatment of prostate cancer depending on patient and disease factors.en_US
dc.subjectCastrate resistant Prostate canceren_US
dc.subjectMetastatic Prostate canceren_US
dc.subjectProstate canceren_US
dc.subjectTherapeutic agentsen_US
dc.titleUnderstanding the role of new systemic agents in the treatment of prostate canceren_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleBJU Internationalen_US
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationSt. Vincent's Health, Fitzroy, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27709828en_US
dc.identifier.doi10.1111/bju.13633en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-5145-6783en_US
dc.identifier.orcid0000-0001-8553-5618en_US
dc.type.austinJournal Articleen_US
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
crisitem.author.deptUrology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

2
checked on Jan 29, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.